Application of apoptosis vesicles in preparation of medicine for preventing or treating heart failure

Improve cardiomyocyte function through exogenous apoptotic vesicle infusion, solve the problem that the metabolic characteristics of myocytes in the treatment of heart failure are not fully considered, significantly improve myocardial function, and provide a new target for mild reduction of heart failure in the ejaculation fraction Treatment protocols demonstrate the potential of apoptotic vesicles in the treatment of heart failure.

CN119074770APending Publication Date: 2024-12-06SUN YAT SEN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411114904.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art does not fully consider the metabolic characteristics of cardiomyocytes in the treatment of heart failure, resulting in misleading diagnosis and poor treatment effect, especially for heart failure (HFmrEF) with mildly reduced ejaculation fraction, and cardiomyocyte dysfunction leads to Complex clinical characteristics are difficult to effectively prevent and treat.

Method used

Exogenous apoptotic vesicles (apoVs) are used to improve cardiomyocyte function through intravenous infusion, analyze the metabolic characteristics of cardiomyocytes and apoptotic vesicles, and maintain cardiac homeostasis, thereby preventing and treating heart failure.

Benefits of technology

Apoptotic vesicles significantly improve myocardial function and alleviate the characterization of heart failure, providing new treatment ideas and solutions for heart failure, especially for apoptosis defects and doxorubicin-induced heart failure mice, demonstrating the use of apoptosis Prospects of vesicles for the treatment of heart failure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004993356390000101
    Figure BDA0004993356390000101
  • Figure BDA0004993356390000111
    Figure BDA0004993356390000111
  • Figure BDA0004993356390000121
    Figure BDA0004993356390000121
Patent Text Reader

Abstract

The invention provides application of apoptosis vesicles in preparation of a medicine for preventing or treating heart failure. According to the invention, the relationship between cardiac homeostasis and apoptosis is found for the first time, and the relationship is proved through myocardial injury and heart failure phenotypes of apoptosis-deficient mice. It is found that exogenous infusion of apoVs can significantly improve the heart functions of apoptosis-deficient mice and Dox-induced mice and significantly alleviate the pathological expression of Dox-induced heart failure mice, which means that treatment of heart failure with apoVs is a promising treatment strategy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to application of apoptotic vesicles in preparing medicine for preventing or treating heart failure. Background Art

[0002] Heart failure refers to a complex clinical syndrome in which ventricular contraction or filling disorders are impaired due to abnormal cardiac structure or function, which in turn causes symptoms and signs. The American Heart Association / American Heart Association / American Heart Failure Association proposed in the "Guidelines for the Management of Heart Failure" released in April 2022 that heart failure should be classified according to left ventricular ejection fraction (LVEF): 1) LVEF ≤ 40% is called heart failure with reduced ejection fraction (HFrEF); 2) LVEF ≥ 50% is called heart failure with preserved ejection fraction (HFpEF); 3) Heart failure with LVEF between HFrEF and HFpEF is renamed heart failure with mildly reduced ejection fraction (HFmrEF); 4) Heart failure with a previous LVEF ≤ 40% and an LVEF increase to > 40% during follow-up is defined as heart failure with improved ejection fraction (HFimpEF), as a subgroup of HFrEF. The treatment of heart failure has different treatment plans based on the above four types.

[0003] 1. Treatment of HFrEF: The “new quadruple” regimen, including renin-angiotensin system inhibitors, beta-blockers, aldosterone receptor antagonists, and SGLT2i.

[0004] 2. Treatment of HFmrEF: There is currently no drug treatment specifically for this type of disease. SGLT2i can reduce heart failure re-hospitalization and cardiovascular death in HFmrEF (Ⅱa, B). In patients with current or previous symptomatic HFmrEF, beta-blockers, ARNi, ACEI or ARB, and aldosterone receptor antagonists can be considered to reduce heart failure hospitalization and cardiovascular mortality.

[0005] 3. Treatment of HFpEF: This classification is due to the large heterogeneity of patients and the large number of comorbidities, especially hypertension, coronary heart disease, atrial fibrillation, diabetes, chronic kidney disease, etc. Some patients have special causes, such as amyloidosis. Treatment is mainly aimed at symptom improvement, cause identification and treatment (such as amyloidosis), and comorbidity management.

[0006] 4. Treatment of late-stage heart failure (Stage D): Prevention is the main approach. Once late-stage heart failure is diagnosed, left ventricular assist device, heart transplantation, palliative care, etc. are used.

[0007] The main deficiencies of the existing technology and the possible breakthroughs of this technology: At present, there are still many gaps in the metabolic characteristics of myocardial cells. Clinically, the classification diagnosis is mainly based on the patient's physical signs, clinical manifestations and LVEF, and the treatment plan is given. There is a misleading phenomenon in the evaluation of LVEF, and the patient's pathophysiological characteristics are not fully considered. Heart failure is ultimately due to the complex clinical manifestations caused by myocardial cell dysfunction. Therefore, it is very important to prevent and treat heart failure by targeting abnormal myocardial cell metabolism and functional improvement. In this technical invention, we discovered for the first time that myocardial cells have a special renewal and replacement mechanism, and for the first time used exogenous apoptotic vesicles to infuse into heart failure mice. It was found that apoptotic vesicles can significantly improve the manifestations of heart failure in mice. It brings new treatment ideas and new solutions to the development of new drugs for heart failure. Summary of the invention

[0008] The purpose of the present invention is to overcome the deficiencies of the prior art and provide the use of apoptotic vesicles in the preparation of drugs for preventing or treating heart failure. The present invention aims to use in vitro induced apoptotic vesicles for the treatment of heart failure, and to analyze the connection between the special metabolic characteristics of cardiomyocytes and apoptotic vesicles, thereby maintaining cardiac homeostasis by improving cardiomyocyte function, thereby achieving the purpose of preventing and treating cardiovascular diseases.

[0009] To achieve the above objectives, the technical solutions adopted are:

[0010] The present invention provides the use of apoptotic vesicles in preparing medicine for preventing or treating heart failure.

[0011] The present invention provides the use of apoptotic vesicles in preparing medicine for preventing or treating myocardial injury.

[0012] The present invention provides application of apoptotic vesicles in preparing medicine for improving the function of myocardial cells.

[0013] The present invention provides application of apoptotic vesicles in preparing medicine for improving cardiac function.

[0014] The present invention provides the use of apoptotic vesicles in preparing medicines for preventing or treating heart diseases.

[0015] In a specific embodiment, the heart failure is heart failure caused by abnormal myocardial cell metabolism.

[0016] In a specific embodiment, the heart failure is apoptosis-deficient induced heart failure.

[0017] In a specific embodiment, the heart failure is DOX-induced heart failure.

[0018] In a specific embodiment, the apoptotic vesicles are apoptotic vesicles derived from mesenchymal stem cells (MSCs).

[0019] Beneficial effects:

[0020] The present invention discovered for the first time the relationship between cardiac homeostasis and cell apoptosis, and demonstrated this through myocardial damage and heart failure phenotypes in apoptosis-deficient mice. The present invention found that exogenous infusion of apoVs can significantly improve cardiac function in apoptosis-deficient mice and Dox-induced mice, and significantly alleviate this pathological manifestation in Dox-induced heart failure mice, which means that the use of apoVs to treat heart failure is a promising therapeutic strategy. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 :Apoptosis-deficient mice show myocardial damage and heart failure. (A, B) Echocardiography and statistical graphs show that 7-month-old Bim + / - and Bim - / - The mice showed heart failure phenotypes, including decreased cardiac function indicators including EF% and FS% and increased LVDs and LVDd. EF: ejection fraction; FS: shortening fraction; LVDs: left ventricular systolic diameter; LVDd: left ventricular diastolic diameter. (C, D) 7-month-old WT and Bim + / - 、Bim - / - Mouse heart size and statistical diagram. HW: heart weight (mg); BW: body weight (g). (E) H&E staining shows that 7-month-old Bim + / - and Bim - / - Mice showed dilated cardiomyopathy. (F,G) WGA staining to detect the area of ​​cardiomyocytes showed that Bim + / - and Bim - / - Hypertrophy of cardiomyocytes in mouse heart tissue, scale bar = 50um. (H, I) Ter119 and WGA staining were performed on heart tissue sections to mark red blood cells and cardiomyocytes. Fluorescence data showed that there were approximately 0.3-0.5 red blood cells around each cardiomyocyte in WT mice, while in Bim mice, there were approximately 0.5 red blood cells around each cardiomyocyte. + / - and Bim - / -This ratio of Bim mice was significantly increased, scale bar = 20um. (J) cTnT immunofluorescence staining showed that compared with WT mice, 7-month-old Bim + / - and Bim - / - Myocardial sarcomeres were disintegrated and destroyed in the mouse heart tissue. cTnT: Structural basis of myocardial relaxation and contraction, scale bar = 10um. (K) TOMM20 immunofluorescence staining was used to mark myocardial fiber mitochondria. The data showed that compared with WT mice, 7-month-old Bim + / - and Bim - / - The mice's mitochondria were swollen and abnormal, indicating that Bim + / - and Bim - / - Mice developed heart failure. Scale bar = 10 μm; *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant.

[0022] Figure 2 :Apoptosis-deficient mice showed myocardial damage and heart failure. (A,B) Echocardiography and statistical graphs showed that the heart phenotype of 8-month-old MRL / lpr mice was abnormal, with significantly higher EF% and FS% values ​​than those of WT mice, significantly lower LVDs and LVDd values ​​than those of WT mice, increased LVPW:s, LVAW:s, and LVAW:d values, and thickened ventricular walls; LVAW:s: left ventricular anterior wall thickness during systole; LVPW:s: left ventricular posterior wall thickness during systole; LVAW:d: left ventricular anterior wall thickness during diastole. (C) The results of the cardiac volume view of 8-month-old WT and MRL / lpr mice showed that the heart of MRL / lpr mice was significantly enlarged compared with that of WT mice. (D) H&E staining results showed that the arrangement of cardiomyocytes in the heart tissue of 8-month-old MRL / lpr mice was disordered. (E,F) WGA staining to detect the area of ​​cardiomyocytes showed that the cardiomyocytes in the heart tissue of MRL / lpr mice were hypertrophic. Scale bar = 10um. (G) Masson trichrome staining data showed that the heart tissue of MRL / lpr mice showed obvious fibrosis, indicating that the mice had myocardial damage. (H) cTnT immunofluorescence staining showed that the heart tissue of 8-month-old MRL / lpr mice had myocardial sarcomere destruction compared with WT mice. Scale bar = 10um. (I) TOMM20 immunofluorescence staining was used to mark myocardial fiber mitochondria. The data showed that mitochondria were abnormal in 8-month-old MRL / lpr mice compared with WT mice. Scale bar = 10um. (J, K) Ter119 and WGA staining were performed on heart tissue sections to mark red blood cells and cardiomyocytes. Fluorescence data showed that there were about 0.3-0.5 red blood cells around each cardiomyocyte in WT mice, while this ratio was significantly increased in MRL / lpr mice. Scale bar = 20um. *p<0.05, **p<0.01, ***p<0.001, ns, not significant.

[0023] Figure 3 :The number of apoptotic vesicles in the heart tissue of apoptosis-deficient mice was significantly reduced. (A, B) Heart tissue-derived EVs were collected and stained for apoVs marker annexin 5 (A5). Nanoflow data showed that compared with WT mice, Bim + / - and Bim - / - There were fewer A5-positive EVs in mouse heart tissue; this suggests that there were fewer apoVs in heart tissue. *p<0.05, **p<0.01, ***p<0.001, ns, not significant.

[0024] Figure 4 :ApoVs infusion can rescue myocardial injury and heart failure in apoptosis-deficient mice. (A, B) After weekly intravenous infusion of apoVs for 4 months, echocardiographic data showed that apoVs could reduce myocardial damage and heart failure in 8-month-old Bim + / - The heart failure phenotype of mice was manifested by increased EF% and FS% values, and significantly decreased LVDs and LVDd values. (C, D) Stereomicroscopy data showed that apoVs infusion significantly alleviated Bim + / - Mouse cardiac hypertrophy phenotype. (E) H&E staining showed that Bim + / - The mouse heart showed hypertrophy symptoms compared with WT mice. Intravenous infusion of apoVs can alleviate this phenotype. Scale bar = 200um. (F, G) WGA staining was used to analyze the area of ​​myocardial cells. The data showed that infusion of apoVs can significantly alleviate Bim + / - Hypertrophy of mouse cardiomyocytes. Scale bar = 20um. (H, I) Ter119 was used to label red blood cells in cardiac tissue, and WGA staining was used to label cardiomyocytes. The data showed that apoVs infusion could reduce Bim in 8-month-old mice. + / - The density of red blood cells infiltrating between myocardial fibers in mice. Scale bar = 20 μm. (J) cTnT immunofluorescence staining showed that apoVs could rescue the myocardial infarction of 8-month-old Bim + / - Abnormally damaged myocardial sarcomeres in mice. Scale bar = 10um. (K) TOMM20 immunofluorescence staining data showed that compared with WT mice, 8-month-old Bim + / - The mitochondria of myocardial fibers in mice were obviously swollen, and apoVs infusion could significantly rescue the mitochondria of Bim in 8-month-old mice. + / - This pathological change in mice suggests that apoVs can significantly rescue myocardial damage in apoptosis-deficient mice. Scale bar = 10 μm; *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant.

[0025] Figure 5:ApoVs infusion can rescue the abnormal cardiac function of apoptosis-deficient mice. (A, B) ApoVs was intravenously infused weekly into apoptosis-deficient MRL / lpr mice. After 4 months, echocardiographic data showed that apoVs could alleviate the cardiac phenotype of 8-month-old MRL / lpr mice, as shown by the abnormally increased EF%, FS%, LVPW:s, and LVPW:d values ​​significantly decreased, and LVDs and LVDd values ​​increased. (C) H&E staining results showed that the myocardial cells in the heart tissue of 8-month-old MRL / lpr mice were arranged in disorder. After apoVs infusion for up to 4 months, this abnormality was significantly improved. (D) Masson trichrome staining results showed that apoVs treatment could significantly improve the myocardial fibrosis of apoptosis-deficient mice, indicating that the myocardial fibrosis of mice was alleviated. (E, F) WGA staining was used to analyze the area of ​​myocardial cells. The data showed that apoVs infusion could significantly alleviate the hypertrophy of myocardial cells in MRL / lpr mice. Scale bar = 20um. (G,H) Ter119 dye was used to label red blood cells in cardiac tissue, and WGA staining was used to label cardiomyocytes. The data showed that apoVs infusion could reduce the ratio of red blood cells to cardiomyocytes in 8-month-old MRL / lpr mice, indicating that red blood cell infiltration and myocardial damage in apoptosis-deficient mice were alleviated. Scale bar = 20um. (I) cTnT immunofluorescence staining showed that apoVs could rescue abnormally damaged myocardial sarcomeres in 8-month-old MRL / lpr mice. Scale bar = 10um. (J) TOMM20 immunofluorescence staining data showed that compared with WT mice, mitochondria in the heart tissue of 8-month-old MRL / lpr mice were abnormal, and apoVs infusion could significantly rescue this pathological change in 8-month-old MRL / lpr mice, indicating that apoVs could significantly rescue abnormal cardiac manifestations in apoptosis-deficient mice. Scale bar = 10um; *p<0.05, **p<0.01, **p<0.001, ns, not statistically significant.

[0026] Figure 6:Apoptotic metabolites apoVs can transfer nuclear material into the nucleus of cardiomyocytes. (A) Mice were intravenously infused with DIR-labeled apoVs at different time points, and in vivo imaging data showed that a small amount of apoVs resided in the heart tissue. (B) After co-culture of apoVs labeled with PKH26 with cardiomyocytes for 24 hours, immunofluorescence data showed that cardiomyocytes could take up apoVs. Scale bar = 10um. (C) After mice were intravenously infused with PKH26-labeled apoVs for 12 hours, 24 hours, and 48 hours, immunofluorescence staining showed that PKH26-labeled apoVs were localized in the heart tissue and gradually approached the cardiomyocyte nucleus over time. Yellow dotted line: cardiomyocyte nucleus; (D) After apoVs were labeled with thymidine analogs 5-ethyl-2-deoxyuridine (EdU) and PKH67 and co-cultured with cardiomyocytes for 24 hours, EdU data showed that the DNA components carried by apoVs could enter the cardiomyocyte nucleus, scale bar = 50um. (E) After co-culture of cardiomyocytes with apoVs for 24 hours, Western blotting data showed that apoVs could upregulate the expression of nuclear proteins in cardiomyocytes, including histones H2A, H2B, H3, and H4. (F) After treatment with apoVs for 12 hours, Western blotting data showed that apoVs could upregulate the expression of SERCA 2a protein, which is considered a marker of cardiomyocyte function. In clinical practice, the downregulation of this protein can be regarded as one of the manifestations of heart failure, indicating that apoVs can improve cardiomyocyte function. (G) Cardiomyocytes were stained with Cell mask Deep Red dye and co-cultured with PKH67-labeled apoVs for 24 hours. Fluorescence data showed that apoVs could accelerate the release of cardiomyocyte-derived extracellular vesicles. (H, I) Cardiomyocytes were labeled with WGA solution and co-cultured with apoVs for 24 hours. Nanoflow data showed that apoVs could significantly accelerate the release of cardiomyocyte-derived extracellular vesicles. (J) After co-culture with apoVs for 12 hours, the exosome inhibitor GW4869 was used to inhibit the release of cardiomyocyte-derived EVs; Western blotting data showed that apoVs could not upregulate the expression of SERCA2a protein without promoting the release of cardiomyocyte-derived EVs, indicating that apoVs relies on the pathway of promoting the release of cardiomyocyte extracellular vesicles to improve cardiomyocyte function.

[0027] Figure 7:Extracellular vesicles derived from cardiomyocytes contain a large amount of nuclear material and can cause cardiomyocyte dysfunction. (A) Compared with extracellular vesicles derived from cardiac fibroblasts (FB-EVs), cardiomyocytes release a large number of extracellular vesicles (CM-EVs, i.e., cardiomyocyte-derived extracellular vesicles, cardiomyocyte-derived vesicles, or cardiomyocyte vesicles) in vitro; NTA analysis data show the size distribution and potential of extracellular vesicles derived from cardiomyocytes. (B) CM-EVs were collected and labeled with PKH26 and Hoechst DNA probes, and fluorescence data showed that CM-EVs contained a large number of DNA fragments. (C, D) After 24 hours of cell culture, the supernatant was collected and centrifuged to obtain extracellular vesicles, and the DNA in the extracellular vesicles was labeled with SYTO-16 DNA fluorescent probe. Nanoflow data showed that CM-EVs and MSC-apoVs contained more DNA fragments than cardiomyocytes (FB-EVs). (E) DAPI staining showed that micronuclei were present in the cytoplasm of both newborn and adult cardiomyocytes of C57 / BL6 mice. Red arrow: micronucleus; scale bar = 20um. (F) Immunofluorescence staining of cardiomyocytes with cTnT and cardiac fibroblasts with phalloidin showed that there were more histone H4 nuclear structural proteins in the cytoplasm of cardiomyocytes. White dashed line: nucleus; scale bar = 10um. (G) Immunofluorescence staining of CD63 and histone H4 showed colocalization of CD63 and histone H4 in intracellular and extracellular cardiomyocytes, indicating that cardiomyocytes excrete nuclear components through extracellular vesicles. *p<0.05, **p<0.01, ***p<0.001, ns, not significant.

[0028] Figure 8: Cardiomyocyte-derived extracellular vesicles contain a large amount of nuclear material and cause cardiomyocyte dysfunction. (A) Western blotting data showed that CM-EVs contained many nuclear structural proteins, such as histones H3, H4, H2A, and H2B. (B) Cardiomyocyte-derived extracellular vesicles were collected and stained with PKH26, and then co-cultured with cardiomyocytes for 24 hours. Fluorescence data showed that cardiomyocytes significantly took up a large amount of cardiomyocyte-derived extracellular vesicles. Scale bar = 10um. (C) Cardiomyocyte-derived extracellular vesicles were collected and co-cultured with cardiomyocytes for 48 hours. 8-Oxoguanine (8-oxoG), a marker of DNA oxidative damage, was used to analyze the effects of cardiomyocyte-derived extracellular vesicles on cardiomyocytes; immunofluorescence data showed that cardiomyocyte-derived extracellular vesicles can cause cardiomyocyte DNA oxidative damage. Scale bar = 20um. (D) After cardiomyocyte-derived extracellular vesicles acted on cardiomyocytes for 48 hours, Western blotting data showed that cardiomyocyte-derived extracellular vesicles could induce cardiomyocyte DNA damage and down-regulate SERCA2a protein expression, suggesting that cardiomyocyte-derived extracellular vesicles could cause cardiomyocyte dysfunction. (E) Nanoflow data showed that cardiomyocyte-derived extracellular vesicles contained many organelles, such as mitochondria (Mito Tracker), lysosomes (Lyso Tracker), and endoplasmic reticulum (ER Tracker).

[0029] Fig. 9:Red blood cells process and internalize damaged nuclear materials expelled from cardiomyocytes. (A) The nucleus and cytoplasm of cardiomyocytes were labeled with Hoechst and WGA, and co-cultured with PKH26-labeled red blood cells for 24 hours. High-content imaging video showed that cardiomyocytes continuously excreted a large amount of nuclear components out of the cell, and red blood cells stationed around cardiomyocytes could process and internalize nuclear materials that were not needed by cardiomyocytes. Yellow dotted line: negative control, inside the red dotted line: the process of red blood cells processing and internalizing nuclear materials expelled from cardiomyocytes; (B) Red blood cells were labeled with the specific marker Ter119, and co-cultured with cardiomyocyte vesicles double-labeled with PKH67 and Hoechst for 24 hours. Immunofluorescence data confirmed that red blood cells could internalize nuclear materials in cardiomyocyte vesicles. Scale bar = 20um. (C) Immunofluorescence data showed that red blood cells residing in cardiomyocyte fibers contained "nuclear-like" components. Scale bar = 20um. (D) Mature erythrocytes in the cardiac cavity and circulating blood of adult mice were stained with SYTO16 (DNA probe) and Ter119 immunofluorescence. Flow cytometry data showed that the proportion of erythrocytes with nuclear material in the cardiac cavity was higher than that in the circulating blood. (E, F) An anemic mouse model was established by intraperitoneal injection of acetanilide (APH, 60 mm / kg, twice a week) into mice for 1 month, and heart samples were collected for further analysis; immunofluorescence data showed that compared with the sham-operated mice, the myocardial fibers of anemic mice had more nuclear centralization and the infiltration of erythrocytes in myocardial fibers increased significantly, indicating that the myocardial damage of anemic mice was severe. Scale bar = 20 um. (G) cTnT immunofluorescence data showed that anemic mice had obvious myocardial sarcomere disintegration and destruction. Scale bar = 20 um. *p<0.05, **p<0.01, ***p<0.001, ns, not significant.

[0030] Fig.10 :Red blood cells internalize and remove nuclear components that are not needed by cardiomyocytes. (A) The video shows that cardiomyocyte-derived vesicles leak a large amount of nuclear material in an environment lacking red blood cells, resulting in a large number of irregular nuclear fragments being released; white arrows: nuclear fragment leakage. (B) Red blood cells without cardiomyocyte-derived extracellular vesicles served as a negative control group. (C) Red blood cells were co-cultured with cardiomyocyte-derived extracellular vesicles, and the video showed that the nuclear components in cardiomyocyte-derived extracellular vesicles were processed and internalized by red blood cells; white arrows: nuclear material of cardiomyocyte-derived extracellular vesicles after being processed by red blood cells.

[0031] Fig.11:Apoptotic metabolites apoVs can rescue Dox-induced heart failure. (A) A heart failure model was established in C57 / BL6 mice by intraperitoneal injection of doxorubicin (Dox). Doxorubicin (5 mg / kg) was intraperitoneally injected weekly for 6 weeks, followed by weekly injection of apoVs for 4 weeks. (B) Survival curve data showed that apoVs could protect Dox-induced heart failure mice from death. (C,D) Echocardiographic data showed that apoVs infusion alleviated the phenotypes of Dox-induced heart failure mice, such as increased EF% and FS% values, and decreased LVDs and LVDd values. (E,F) Stereological imaging data showed that the heart size of Dox-induced heart failure mice was smaller than that of sham-operated mice, and apoVs infusion could rescue the abnormal cardiac phenotype caused by Dox. HW: heart weight; BW: body weight; scale bar = 20 mm. (G) H&E staining showed that the heart size of mice with Dox-induced heart failure was smaller than that of mice in the sham operation group, and apoVs infusion could rescue the Dox-induced heart microsomia. Scale bar = 200um. (H,I) WGA staining showed that the cardiomyocyte area of ​​mice with Dox-induced heart failure was smaller than that of mice in the sham operation group, and apoVs could improve the abnormal area of ​​cardiomyocytes in mice with Dox-induced heart failure. Scale bar = 20um. (J) cTnT immunofluorescence staining showed that apoVs could improve the abnormal morphology of cardiac sarcomeres in mice with Dox-induced heart failure. Scale bar = 10um. (K) TOMM20 immunofluorescence staining was used to mark the mitochondria of myocardial fibers, and the data showed that the mitochondria of mice with Dox-induced heart failure were abnormally swollen compared with those of mice in the sham operation group. Scale bar = 10um.

[0032] Fig.12 :Myocardial cells maintain cardiac homeostasis through nuclear component renewal mechanism. (A) Schematic diagram of the construction of mouse bone marrow transplantation chimeric model. (B) 4 months after the mouse chimeric model surgery, flow cytometry was used to detect the ratio of GFP-positive cells in the bone marrow of chimeric mice. (C) Schematic diagram of mouse heterotopic heart transplantation surgery. (D) After irradiation ablation of WT mouse bone marrow cells, bone marrow cells from GFP fluorescent mice were immediately transplanted. 4 months later, the hearts of chimeric model mice were collected and sectioned and stained. The results showed that there were dot-like GFP-positive areas in the hearts of chimeric model mice, indicating that cardiomyocytes carried components derived from GFP-positive cells for subcellular structural replacement. (E) The heart of a WT mouse was transplanted into a GFP mouse to establish a cardiac heterotopic transplantation model. 2 weeks later, immunofluorescence staining data showed that the WT mouse donor heart contained a large number of GFP-positive cardiomyocytes, indicating that the cardiomyocytes in the donor heart tissue had replaced substances in the body of the GFP fluorescent mouse. DETAILED DESCRIPTION

[0033] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0034] Example 1

[0035] 1. Materials and methods involved in the present invention

[0036] 1. Mice

[0037] The transgenic model B6.MRL-Fas constructed by exogenous apoptosis receptor FAS deficiency lpr / J (MRL / lpr) mice, and the endogenous apoptosis defect model constructed by knockout of the mitochondrial-related Bim gene B6.129S1-Bcl2l11 tm1.1Ast / J mice (Bim + / - and Bim - / - CAG-EGFP green fluorescent mice were purchased from Jackson Laboratory and housed in the barrier environment of Experimental Area A of the Experimental Animal Center of the North Campus of Sun Yat-sen University. C57BL / 6 mice were purchased from the Experimental Animal Center of the East Campus of Sun Yat-sen University and housed in the mouse experimental area of ​​Area A and Area F of Hemu Building of the Experimental Animal Center of the North Campus of Sun Yat-sen University. All animal experiments were in accordance with the ethics of the Experimental Animal Center of Sun Yat-sen University (ethical approval number: SYSU-IACUC-2023-000736).

[0038] 2. Antibodies and Reagents

[0039] All antibodies, chemicals, kits, and other resources used in this study are listed in Tables 1 and 2.

[0040] Table 1 Materials and reagents

[0041]

[0042]

[0043]

[0044] Table 2 Instruments and equipment

[0045]

[0046]

[0047] 3. Mouse Cardiac Ultrasound Detection and Analysis Method

[0048] The apoptosis-deficient model MRL / lpr mice and Bim KO mice were raised in a barrier environment for more than 7 months, and wild-type mice of the same age were used as the control group. The mice were anesthetized by isoflurane gas anesthesia (isoflurane flow rate was 0.3-0.5L / min), fixed on the ultrasound operation table, and the mouse limbs were conductively monitored for heart rate changes with conductive paste. The mouse chest area was shaved of hair, and an ultrasonic coupling agent was used as a conductive medium. The MX400 ultrasound probe was selected to find the mouse heart area, and the mouse M mode and B mode were measured. The long axis and short axis of the mouse heart were measured for subsequent cardiac function analysis. After the mouse heart rate reached a stable level (about 400 times / min), the M mode and B mode of the mouse ultrasound image were recorded. Vevo3100 software was used to analyze the ultrasound results, and the ejection fraction (EF) and fractional shortening (FS) parameters were selected as the main indicators for evaluating the mouse cardiac function. The left ventricular systolic diameter (LVSD) was measured. The left ventricular diastole diameter (LVDd), the left ventricular anterior wall thickness (LVAW) and the left ventricular posterior wall thickness (LVPW) were used as auxiliary diagnostic indicators.

[0049] 4. Wheat germ agglutinin-labeled cardiomyocyte membrane staining

[0050] Wheat-germ agglutinin (WGA) stain was used to fluorescently label the myocardial cell membrane and evaluate the size of the cross-sectional area of ​​myocardial cells. The hearts of wild-type mice and apoptosis-deficient mice of the same age were collected by 4% neutral paraformaldehyde perfusion method and prepared into paraffin tissue sections. After the sections were baked, dewaxed and rehydrated, antigen repair was performed with 1X sodium citrate antigen repair solution at 95°C for 15 minutes. After the sections were cooled to room temperature, they were washed 3 times with PBS, the target area in the immunohistochemistry pen circle was not treated with heart tissue membrane, and it was blocked with 5% BSA in PBS at room temperature for 1 hour, washed 3 times with PBS, and WGA working solution was prepared with PBS buffer to make the concentration of WGA staining working solution 10μg / mL, reacted at room temperature in the dark for 1 hour, washed 3 times with PBS, sealed with mounting medium, dried, and photographed with laser confocal microscope; Image J software was used to analyze the cross-sectional area of ​​each myocardial cell.

[0051] 5. Masson trichrome staining experiment

[0052] Prepare heart samples of MRL / lpr mice with apoptosis defect model and prepare paraffin sections; after the paraffin sections were waxed at 60°C, dewaxed, and rehydrated in a gradient manner, they were washed with PBS three times, and the target tissue area was circled with a histochemical pen. The heart tissue was covered with solution A in the Masson trichrome staining kit overnight, for about 15 hours; the sections containing solution A were placed in a 65°C oven for incubation for 30 minutes, and rinsed with tap water for 30 seconds to fade the tissue. At the same time, solution D and solution F in the components were placed in a 65°C oven for preheating; solution B and solution C in the components were mixed in equal volumes at a ratio of 1:1, and used immediately after preparation. The mixed solution B+C was covered with the heart tissue for reaction for 1 minute, and the residual staining solution was rinsed with running water to remove the acid differentiation solution, with a ratio of concentrated hydrochloric acid: anhydrous ethanol = 1:100, and the heart tissue sections were Place in ethanol acid differentiation solution until the nucleus is black and the background around the tissue is clean and colorless; add preheated D solution and incubate for 6 minutes; rinse with running water until the rinsing solution turns from red to colorless; add preheated E solution to stain the collagen in the heart for 1-2 minutes; drain E solution slightly, add F solution directly without washing, incubate for 20-30 seconds, and rinse and differentiate the slices in three cylinders of 1% glacial acetic acid aqueous solution, each cylinder for about 7 seconds. The third glacial acetic acid differentiation step needs to be observed under an optical microscope to avoid excessive differentiation of the tissue; dehydrate the slices in three cylinders of anhydrous ethanol for 3 seconds-5 seconds-5 seconds, put the slices in xylene for transparency for 5 minutes, seal the slices with neutral resin, and observe the degree of cardiac fibrosis under an inverted fluorescence microscope after drying.

[0053] 6. Eosin-Hematoxylin Staining Experiment

[0054] The heart tissues of apoptosis-deficient mice and wild-type mice were prepared into paraffin sections. The sections were baked at 60°C for 1 hour, dewaxed in xylene, rehydrated, and stained with hematoxylin for 5 minutes. After staining, they were washed with ultrapure water for 30 seconds, differentiated with 1% hydrochloric acid ethanol differentiation solution for 4 seconds, and the ratio of 1% hydrochloric acid ethanol differentiation solution was 36% concentrated hydrochloric acid: 75% alcohol = 1:99. After differentiation, they were rinsed in ultrapure water for 30 seconds; ammonia working solution was used for blueing for 2 minutes; they were sequentially passed through the following histochemical cylinders: ultrapure water (30 seconds) - ultrapure water (30 seconds) - 95% alcohol (30 seconds) - 95% alcohol (30 seconds); after eosin staining for 2 minutes, the sections were dehydrated by 95% alcohol (30 seconds) - 95% alcohol (30 seconds) - 100% alcohol (30 seconds) - 100% alcohol (30 seconds), and then transparentized twice with xylene for 30 seconds each time, sealed with neutral resin, dried, and scanned by a slice scanner.

[0055] 7. Isolation, extraction and culture of mouse mesenchymal stem cells

[0056] Subcutaneous adipose tissue was extracted from C57BL / 6 mice within 1-2 weeks after birth. The abdominal skin was cut open, the mouse skin was gently peeled off, the inguinal lymph nodes were removed, and the white adipose tissue from the mouse groin, armpits and back was separated. The separated adipose tissue was placed in PBS buffer containing 2% double antibody and placed on ice. In a biosafety cabinet, the separated mouse adipose tissue was washed 3 times with PBS buffer containing 2% double antibody to avoid contamination. The adipose tissue was minced with a scalpel and 4 mg / mL concentration of Type 2 antibody was added. I collagenase and 8 mg / mL DispaseⅡ dispersase were mixed in equal volumes at a ratio of 1:1 to obtain the digestion enzyme working solution. The digestion enzyme working solution was preheated to 37°C in advance, and 3-5 times the volume of the digestion enzyme working solution was added to the minced mouse adipose tissue. The mixture was incubated at 37°C in a constant temperature shaker at 180 rpm for 1 hour. An equal volume of complete culture medium containing serum was added to terminate the enzyme digestion reaction, and the cells were filtered through a cell strainer with a pore size of 70 μm to collect the single cell suspension. The cells were collected by centrifugation at 1500 rpm for 10 minutes, resuspended in mouse MSCs complete culture medium, plated, and replaced with medium after 48 hours. The cells were passaged to P1-P3 for experiments.

[0057] 8. Identification of surface molecular markers of mouse MSCs

[0058] After digestion of MSCs from P1 to P3, the surface markers of stem cells were stained. Antibodies CD45 and CD11b, which are negative for stem cell expression, and CD44 and CD29, which are positive markers, were selected. MSCs were digested with EDTA-free trypsin and centrifuged at 1500 rpm for 5 minutes to collect single cell suspension. The cell concentration was adjusted to 1 x 10 7 cells / mL, 2x10 6 The cells were added to a 96-well round-bottom plate for flow cytometry, centrifuged at 1500rpm for 5 minutes, and the supernatant was discarded; the above flow cytometry antibodies were diluted according to the antibody instructions, the antibody diluent was 0.5% BSA in PBS (Facs buffer), the cells were resuspended with the antibody working solution, 50uL per well, placed on ice and protected from light for 30 minutes, 200uL Facs buffer was added to terminate the staining reaction, centrifuged at 1500rpm for 5 minutes, the supernatant was discarded, 150uL Facs buffer was added to resuspend the stained cells, and the expression of MSCs surface molecular markers was detected on an intelligent flow cytometer.

[0059] 9. Mouse MSCs multidirectional differentiation induction and staining methods

[0060] (1) Mouse MSCs osteogenic differentiation steps: ADSCs were seeded in a 12-well plate. When the cell confluence reached 80%-90%, the cell culture medium was removed and mouse MSCs osteogenic differentiation induction medium was added. The induction medium was replaced every two days for 21 days. The osteogenic differentiation induction medium was gently removed and the cells were washed with PBS three times. 4% neutral paraformaldehyde was added to fix the cells for 5 minutes. Alizarin red staining was performed for 3-10 minutes to mark calcium nodules. The cells were observed and photographed under an inverted fluorescence microscope.

[0061] (2) Steps for inducing adipogenic differentiation of mouse MSCs: Mouse MSCs were seeded in a 12-well plate. When the cell confluence reached more than 100%, adipogenic differentiation induction solution was added to induce cell adipogenic differentiation. The cells were observed every two days and the adipogenic differentiation induction solution was replaced. The induction lasted for 9-10 days. When lipid droplets were clearly observed, the adipogenic differentiation induction solution was removed, the cells were washed with PBS three times, the cells were fixed with 4% neutral paraformaldehyde for 15 minutes, washed with ultrapure water three times, the Oil Red O dye solution was filtered with a filter to remove undissolved precipitates in the dye solution, and the Oil Red O dye solution was added for staining for 15 minutes; the dye solution was removed, the cells were washed with ultrapure water three times, and the images were observed under an inverted fluorescence microscope.

[0062] 10. Isolation, purification and identification of apoVs from mouse MSCs

[0063] (1) Isolation and purification steps: When mouse MSCs are cultured to a confluence of 90%-100%, α-MEM basal medium containing 500 nM staurosporine (STS) is added to induce cell apoptosis for 6 hours. All cells and vesicles in the culture dish are collected by vigorous blowing. The centrifuge is precooled to 4°C. The centrifugation conditions are as follows: 800g, 10 minutes, 4°C, the cells in the precipitate are removed, and the supernatant is collected for the next step of centrifugation; 2000g, 10 minutes, 4°C, the cell debris in the precipitate is removed, and the supernatant is collected; 16000g, 30 minutes, 4°C, the supernatant is removed, and the precipitate after centrifugation is collected as apoVs (apoptotic vesicles).

[0064] (2) Transmission electron microscopy identification of apoVs morphology: The concentration of freshly isolated and purified apoVs was adjusted to 1x10 10 / mL, resuspend apoVs with PBS, take 10uL of the suspension and drop it on the copper grid for electron microscopy. After the vesicles are adsorbed and stabilized on the copper grid, add 10uL of 2% tungstic acid phosphate solution with a PH value of 6.5 to react with the vesicles for 2 minutes. After the electron microscopy sample is dried, the vesicle morphology is photographed with a transmission electron microscope.

[0065] (3) Western blotting to detect the expression of apoVs-specific marker proteins: The purified apoVs were collected in a 1.5 mL EP tube, the liquid was aspirated, and RIPA lysis buffer containing phosphatase inhibitors and protease inhibitors was added to collect apoVs proteins. Mouse MSCs were used as negative controls. The protein samples were ultrasonically lysed and centrifuged, and the protein concentration of the samples was adjusted by BCA protein concentration determination for subsequent electrophoresis and membrane transfer operations; after the protein samples were transferred to the PVDF membrane, they were incubated with the primary antibody working solution in a 4°C cold storage overnight; the primary antibodies selected extracellular vesicle markers CD63, CD9 and TSG101, apoptosis-related proteins Fas and Calreticulin, and intracellular reference protein β-actin. After the primary antibody incubation was completed, the subsequent operations were consistent with the conventional Western blotting method.

[0066] (4) Zeta View analysis of apoVs particle size and potential: Freshly extracted mouse MSCs-derived apoVs were resuspended in filtered PBS, and the Zeta View instrument quality control was performed in advance using NTA standards. The apoVs were diluted to an appropriate concentration, and 1 mL was injected for analysis of the apoVs particle size and potential. The apoVs particle size and potential were analyzed using Zeta View software.

[0067] (5) Analysis of the expression of apoVs surface molecular markers using a high-resolution live cell imaging system (SIM): Freshly extracted apoVs were stained with PKH26 membrane dye, and apoVs were fluorescently stained with the surface molecular marker Annexin V, and then photographed using a high-resolution live cell imaging system to analyze the expression of apoVs surface molecular markers.

[0068] (6) Single-particle nanoflow cytometry analysis of the proportion of apoVs positively expressing Annexin V: apoVs were labeled with PE-Annexin V flow cytometry antibody. Annexin V has been identified as a specific surface molecular marker of apoVs. PE-Annexin V was diluted in 1X Annexin V binding buffer at a dilution concentration of 1:100 and incubated at room temperature in the dark for 15 min. After the reaction, 4 times the volume of 1X Annexin V binding buffer was added to terminate the staining reaction. The proportion of apoVs derived from MSCs positively expressing Annexin V was measured using a single-particle nanoflow cytometer. 1X Annexin V binding buffer was used as a blank control group.

[0069] 11. MSCs colony forming unit (CFU) detection method

[0070] After mouse-derived MSCs were extracted and amplified, the cells were digested, resuspended, and counted; 100 MSCs were seeded in a 6-well plate so that the cells showed a sparse single cell growth density; they were cultured in a cell culture incubator for 10 days, and fresh culture medium was replaced every 3 days. After the cells were observed to form clonal units under a microscope, the culture medium was removed, the cells were washed 3 times with PBS, and 4% neutral paraformaldehyde was added to fix them at room temperature for 20 minutes; the paraformaldehyde was removed, the cells were washed 3 times with PBS, and they were stained with 0.1% crystal violet solution for 10 minutes; the staining solution was removed, the residual staining solution was fully washed with PBS, and after the well plate was dried, the MSCs cloning status was recorded with a well plate scanner.

[0071] 12. Steps for isolation, extraction and culture of mouse adult cardiomyocytes

[0072] (1) Prepare calcium precipitation solution and myocardial cell digestion solution: benchtop solution + type II collagenase (1 mg / mL concentration);

[0073] (2) Preparation of calcium precipitation solution: freshly prepared and used immediately:

[0074] A.CaCl2,100mM(0.555g / 50mL ddH2O)

[0075] B.1% BSA (0.5g / 50mL perfusion fluid)

[0076] Ca 2+ I buffer:12.5μm (0.6μL / 5mL 1% BSA)

[0077] Ca 2+ II buffer:100μm (5μL / 5mL 1% BSA)

[0078] Ca 2+ III buffer:400μm (20μL / 5mL 1% BSA)

[0079] Ca 2+ IV buffer:900μm (45μL / 5mL 1% BSA)

[0080] The above liquids were mixed on a clean bench, filtered through a 0.22 μm pore size filter, and freshly prepared.

[0081] (3) Soak the Langendorf perfusion instrument in 75% alcohol for 2 hours in advance, clean the instrument pipeline with sterile ultrapure water for 3 times, and then clean the instrument pipeline with sterile perfusion fluid for 2 times; reserve 10 ml of perfusion fluid after flushing, pour out fresh perfusion fluid and pre-cool it in a -80 refrigerator; fix the perfusion syringe and flush with pre-cooled perfusion fluid, keeping it below the liquid surface throughout the process to prevent bubbles; anesthetize the mouse with Su Mian Xin + Shu Tai intramuscular injection, and inject heparin anticoagulation intraperitoneally at a dose of 20 U / 25 g; fix the mouse; quickly cut the chest cavity; quickly free the heart and retain the main aorta in the heart Arterial blood vessels; insert the perfusion needle from the aorta of the heart, fix it, and gently inject pre-cooled perfusion fluid to drain the residual blood in the heart; remove the heart and hang it on the Langendorf perfusion instrument, and turn on the peristaltic pump; pre-digest with 5mL digestive enzyme, and then use 20mL digestive enzyme for cyclic digestion after the pre-digestion. The perfusion speed of the digestive solution is maintained at 1 second per drop, and the digestion time is about 15 minutes. When the heart is digested into a water drop shape, cut the heart, remove the atrium and right ventricle, tear it into pieces, blow with a Pasteur tube, pour in 5mL of fresh digestive enzyme, and let it settle in a 15mL centrifuge tube for 6 minutes.

[0082] (4) Cardiomyocyte recalcification step: The digested cardiomyocytes are precipitated in four calcium precipitation solutions from low to high concentrations. Each precipitation lasts for 6 minutes. The precipitates are cardiomyocytes. After the cardiomyocytes are recalcified and precipitated, fibroblasts and dead cells can be effectively removed. After the cell sedimentation is completed, the cells are filtered with a 100μm particle size cell filter to remove undigested heart tissue. Before plating, the culture dish is coated with 1% Matrigel and placed in a 37°C incubator for 15 to 30 minutes. The cardiomyocytes are resuspended with 2mL plating medium and cultured in the coated cell culture dish. After the cells adhere to the wall for 2-3 hours, the plating medium is gently removed, and the culture medium is added to continue culturing. This is used for subsequent experimental detection.

[0083] 13. Heterotopic heart transplantation between CAG-EGFP green fluorescent mice and C57BL / 6 mice

[0084] (1) Obtaining the donor heart: A normal C57BL / 6 mouse heart weighing about 20-25 g without fluorescence expression was selected as the donor heart. A mixture of Suminxin and Shutai dissolved in physiological saline at a ratio of 1:1 was used as an intramuscular anesthetic. When the mouse was sufficiently anesthetized, the operation was started. The mouse was fixed in a supine position. The abdominal cavity of the mouse was cut open, heparin was injected from the inferior vena cava, and the abdominal aorta of the mouse was cut open to bleed. The chest cavity of the mouse was cut open to expose the inferior vena cava, and heparin saline was perfused from the inferior vena cava to drain the blood in the heart cavity. The inferior vena cava was ligated with 8-0 nylon thread. After ligation, the superior vena cava was exposed and ligated with 8-0 nylon thread. The aorta and pulmonary artery were exposed and cut below the bifurcation of the blood vessels. The remaining large blood vessels of the heart were ligated with 8-0 nylon thread, and the recipient heart was freed after the ligation. The recipient heart was placed in physiological saline for later use, and the saline was placed on ice.

[0085] (2) Transplantation of recipient heart into donor mouse: transplant the free heart of C57BL / 6 mouse into the neck of CAG-EGFP green fluorescent mouse; anesthetize the GFP green fluorescent mouse with intramuscular injection of Suminxin + Shutai, fix the mouse in supine position; cut the neck of GFP green fluorescent mouse, separate the external jugular vein and common carotid artery of GFP mouse, clamp the proximal end with vascular clamp, ligate the distal end with silk thread, cut it off and fix the cannula to the stump with silk thread, wrap the aorta of C57BL / 6 mouse donor heart over the common carotid artery of GFP mouse, wrap the pulmonary artery over the external jugular vein of GFP mouse, fix it with silk thread, open the vascular clamp to restore blood flow, suture the skin, and complete the heart transplantation. Place the postoperative mouse on a 37℃ rewarming blanket to wait for the mouse to wake up, and transfer the postoperative mouse to a clean cage.

[0086] 14. EdU labeling of apoVs to detect the DNA components carried by apoVs entering the nucleus of cardiomyocytes

[0087] The mouse-derived MSCs were incubated with EdU incubation solution to mark the DNA components in their nuclei, with an incubation concentration of 50 mM and an incubation time of 6 hours. The EdU incubation solution was removed, and 500 nM STS working solution was added to induce apoptosis of the MSCs after EdU labeling. ApoVs were extracted, and the steps were similar to those mentioned above. Since apoVs would carry a large amount of nuclear nucleic acid components from the mother cells, apoVs would carry nucleic acid components labeled with EdU at this time. The EdU-labeled apoVs were stained with PKH26, and apoVs from the same cell type that were not labeled with EdU were used as a negative control group. After PKH26 staining, they were added to SD rat neonatal cardiomyocytes for co-culture for 24 hours. The culture medium was removed, and PBS was added for washing 3 times to fully remove the apoVs that were not taken up by the cardiomyocytes, and 4% neutral paraformaldehyde was added for fixation at room temperature for 20 minutes to perform EdU. Click reaction, the experimental steps are the same as before; counterstaining with cTnT immunofluorescence to mark cardiomyocytes, and counterstaining with DAPI dye to mark cell nuclei, the steps are the same as before; laser confocal imaging is used to analyze the number of EdU-positive cardiomyocytes. The presence of EdU-positive staining in the nucleus of cardiomyocytes indicates that the nucleic acid components derived from apoVs have been taken up.

[0088] 15. Cardiomyocyte vesicle uptake method

[0089] The supernatant of the cultured cardiomyocytes of SD rats within 1-3 days after birth was collected and subjected to gradient centrifugation at 800g, 4°C, 10 minutes, to remove the precipitate and collect the supernatant; the supernatant was centrifuged at 2000g, 4°C, 10 minutes, to remove the precipitate and collect the supernatant; the supernatant was centrifuged at 16000g, 4°C, 30 minutes, to remove the supernatant and collect the precipitate; the vesicles effluxed by cardiomyocytes were marked with PKH26 or PKH67 dyes, added to the cardiomyocytes for co-culture for 24 hours, the supernatant was removed, the cells were washed 3 times with PBS, and fixed with 4% neutral paraformaldehyde for 15 minutes; 0.5% Triton-X 100 was permeabilized at room temperature for 10 minutes, washed 3 times with PBS, and 5% BSA in PBS was added to block the cells at room temperature for 1 hour; cTnT primary antibody incubation working solution was added and incubated overnight at 4°C to mark the cardiomyocytes, and the subsequent operations were consistent with the immunofluorescence staining steps; the apoVs uptake experimental steps were consistent with the above.

[0090] The rest of the experimental steps were consistent with the previous description.

[0091] 16. High-content analysis method of co-culture of red blood cells and cardiomyocytes

[0092] Blood was collected from the tail vein of adult SD rats and centrifuged at 800 g to collect red blood cells, which were washed twice with RPMI1640 and labeled with PKH26 membrane dye according to the instructions. Cardiomyocytes were extracted from SD rat pups within 1-3 days after birth, and the cardiomyocyte membrane was labeled with WGA dye. The cardiomyocyte culture medium was removed, and the cells were washed three times with PBS. A mixture of HBSS containing WGA was added, with WGA:HBSS = 1:200. The cells were placed in a cell culture incubator for 20 minutes, the staining working solution was removed, and the cells were washed three times with HBSS. The cells were stained with Hoechst. The cardiomyocyte nuclei were labeled with WGA dye and Hoechst dye. The ratio of Hoechst dye working solution was Hoechst: PBS = 1:2000. The dye working solution was added to the cardiomyocytes and reacted in an incubator away from light for 5 minutes. The cells were washed with PBS three times to remove the residual dye. The PKH26-labeled red blood cells were added to the cardiomyocytes labeled with WGA dye and Hoechst dye and co-cultured for 48 hours. The co-cultured red blood cells and cardiomyocytes were placed in a high-content analysis imaging system, and a picture was taken every 15 minutes for a total of 48 hours. A video was made to observe the interaction between the cardiomyocytes and red blood cells.

[0093] 17. High-content analysis of extracellular vesicles co-cultured with erythrocytes and cardiomyocytes

[0094] CM-EVs from the culture supernatant of rat neonatal cardiomyocytes and anucleated red blood cells from the circulating blood of adult rats were collected according to the aforementioned method, and the extracellular vesicles derived from cardiomyocytes were labeled green with PKH67 membrane dye, and the staining steps were the same as described above; after staining, PBS was washed three times, and Hoechst nucleic acid dye was added to label the nucleic acid components of CM-EVs; the labeling steps were the same as described above; red blood cells were stained with PKH26 membrane dye, and the steps were the same as described above; PKH67+Hoechst-labeled CM-EVs and PKH26-labeled anucleated red blood cells were placed in a high-content live cell analysis imaging system for co-culture for 24 hours to observe the interaction between cardiomyocyte extracellular vesicles and red blood cells.

[0095] 18. Method for staining circulating red blood cells and cardiac red blood cells with nucleic acid dyes

[0096] Cardiac blood was collected from the mouse cardiac cavity to obtain the erythrocytes in the cardiac cavity, and blood was collected from the mouse tail vein to obtain the circulating erythrocytes away from the heart. After centrifugation, the single cell suspension of the circulating erythrocytes and the erythrocytes in the cardiac cavity was collected, and the SYTO-16 probe that can mark the nucleic acid components in the membrane without breaking the membrane was added. The incubation concentration was 1:1000in PBS. The cells were incubated at room temperature in the dark for 1 hour, washed 3 times with PBS, and 150uL of the single cell suspension of erythrocytes was added. The difference in nucleic acid components carried by the two types of erythrocytes was analyzed by intelligent flow cytometer; to verify whether the nucleic acid components carried by erythrocytes are located inside or outside the cells, we used DNAse for digestion. The concentration of DNAse working solution was 1mg / mL. The DNAse working solution was incubated with erythrocytes at room temperature for 15 minutes, and 5 times the volume of PBS was added to terminate the enzyme reaction. 800g, centrifuged for 3 minutes, collected the erythrocyte suspension, washed 2 times with PBS, and then SYTO-16 staining was performed. The steps were similar to the previous ones, and the nucleic acid carrying situation was analyzed by intelligent flow cytometer.

[0097] 19. Method for constructing chimeric model of bone marrow transplantation between GFP green fluorescent mice and C57BL / 6 mice

[0098] GFP fluorescent mice aged 3-4 weeks were selected, and their whole bone marrow was transplanted into the bone marrow of non-fluorescent C57BL / 6 mice; C57BL / 6 mice aged 8-10 weeks were selected; C57BL / 6 mice were irradiated with a dose of 4.5 Gy once and irradiated twice with an interval of 3 hours. The bone marrow cells of C57BL / 6 mice were ablated by two irradiations, so that they lost their regenerative ability; whole bone marrow was extracted from the tibia of GFP green fluorescent mice, centrifuged at 400g for 10 minutes, 2 mL of red blood cell lysis solution was added, lysed at room temperature for 5 minutes, and 5 times the volume of PBS buffer was added to terminate the lysis reaction; centrifuged at 400g for 10 minutes, and the cells were counted; the extracted whole bone marrow from GFP green fluorescent mice was injected into the irradiated C57BL / 6 mice through the tail vein, and the injection volume of each mouse was 1.5x10 6 Whole bone marrow cells from GFP mice were obtained; aseptic operation was paid attention to throughout the process to avoid infection; 2 weeks after surgery, mice were fed drinking water containing Baytril antibiotics; the Baytril ratio was: 2.5mL 5% Baytril + 250mL sterile water; within one week after surgery, the mice were weighed every other day to observe their weight. No weight loss, or a rebound after a decrease, proved that the bone marrow transplantation was successful; 4 months after modeling, the mice were killed, and the mouse hearts were collected and fixed with 4% neutral paraformaldehyde for subsequent paraffin sectioning or frozen sectioning for histological analysis; the mouse tibia tissue was collected, the whole bone marrow of the chimeric mouse was extracted, and the red blood cell lysis operation was performed with the same operating steps as before. The intelligent flow cytometer was used to detect the proportion of GFP green fluorescence-positive cells in the bone marrow of the chimeric mouse model to evaluate the success of the modeling.

[0099] 20. Heterotopic heart transplantation between CAG-EGFP green fluorescent mice and C57BL / 6 mice

[0100] (1) Obtaining the donor heart: A normal C57BL / 6 mouse heart weighing about 20-25 g without fluorescence expression was selected as the donor heart. A mixture of Suminxin and Shutai dissolved in physiological saline at a ratio of 1:1 was used as an intramuscular anesthetic. When the mouse was sufficiently anesthetized, the operation was started. The mouse was fixed in a supine position. The abdominal cavity of the mouse was cut open, heparin was injected from the inferior vena cava, and the abdominal aorta of the mouse was cut open to bleed. The chest cavity of the mouse was cut open to expose the inferior vena cava, and heparin saline was perfused from the inferior vena cava to drain the blood in the heart cavity. The inferior vena cava was ligated with 8-0 nylon thread. After ligation, the superior vena cava was exposed and ligated with 8-0 nylon thread. The aorta and pulmonary artery were exposed and cut below the bifurcation of the blood vessels. The remaining large blood vessels of the heart were ligated with 8-0 nylon thread, and the recipient heart was freed after the ligation. The recipient heart was placed in physiological saline for later use, and the saline was placed on ice.

[0101] (2) Transplantation of recipient heart into donor mouse: transplant the free heart of C57BL / 6 mouse into the neck of CAG-EGFP green fluorescent mouse; anesthetize the GFP green fluorescent mouse with intramuscular injection of Suminxin + Shutai, fix the mouse in supine position; cut the neck of GFP green fluorescent mouse, separate the external jugular vein and common carotid artery of GFP mouse, clamp the proximal end with vascular clamp, ligate the distal end with silk thread, cut it off and fix the cannula to the stump with silk thread, wrap the aorta of C57BL / 6 mouse donor heart over the common carotid artery of GFP mouse, wrap the pulmonary artery over the external jugular vein of GFP mouse, fix it with silk thread, open the vascular clamp to restore blood flow, suture the skin, and complete the heart transplantation. Place the postoperative mouse on a 37℃ rewarming blanket to wait for the mouse to wake up, and transfer the postoperative mouse to a clean cage.

[0102] 2. Experimental Results

[0103] 1. Apoptosis-deficient mice show myocardial damage and heart failure

[0104] Apoptosis is involved in morphogenesis during cardiac development; it is well known that cardiomyocyte apoptosis occurs during the embryonic period, and after birth, apoptosis is also involved in the morphogenesis of the conduction system, including the atrioventricular, sinoatrial, atrioventricular nodes, and His bundle. Although studies have reported that cardiomyocyte apoptosis is closely related to acute and old myocardial infarction, the relationship between cardiac homeostasis and systemic apoptosis and its metabolite apoVs is still unclear. Therefore, we used apoptosis-deficient models, including MRL / lpr mice and Bim knockout mice (Bim + / - and Bim - / - ) to explore the role of apoptosis in cardiac homeostasis. + / - Mouse and Bim- / - The mice all showed a heart failure phenotype, characterized by decreased ejection fraction (EF%) and fractional shortening (FS%), accompanied by increased left ventricular systolic diameter (LVDs) and left ventricular diastolic diameter (LVDd) values ​​( Figure 1 AB). However, we raised MRL / lpr mice to 8 months of age. Compared with wild-type mice at 8 months of age, the EF% and FS% values ​​of MRL / lpr mice were significantly increased, and the LVDs and LVDd values ​​were decreased, which was consistent with the results of the 7-month-old Bim + / - and Bim - / - The echocardiographic features of mice were different ( Figure 2 AB). In addition, the left ventricular wall of 8-month-old MRL / lpr mice was significantly thickened, and the values ​​of LVAW:s, LVAW:d, and LVPW:s in cardiac function analysis were increased ( Figure 2 AB), suggesting that 8-month-old MRL / lpr mice may develop hypertrophic cardiomyopathy (HCM). Therefore, we collected the hearts of apoptosis-deficient mice for further histopathological analysis. Cardiac stereomicroscope images showed that 7-month-old Bim + / - Mouse and Bim - / - Mice, 8-month-old MRL / lpr mice showed larger heart size ( Figure 1 C, Figure 2 C), the ratio of heart weight (HW) to body weight (BW) was higher than that of WT mice ( Figure 1 D), Hematoxylin and eosin (H&E) staining and WGA staining were used to analyze the myocardial histological changes. The WGA staining data showed that Bim + / - Mouse and Bim - / - Mice, 8-month-old MRL / lpr mice had increased cardiomyocyte area, indicating myocardial hypertrophy ( Figure 1 FG, Figure 2 EF), H&E staining shows that 7-month-old Bim + / - and Bim - / - Mice exhibited cardiac chamber dilation consistent with clinical dilated cardiomyopathy (DCM). Figure 1 E). Studies have shown that HCM is always diagnosed by histopathological features of cardiomyocyte hypertrophy, disorder, and increased myocardial fibrosis. Therefore, we used H&E staining and Masson's trichrome staining to elucidate the cardiac phenotype of MRL / lpr mice. The results of H&E staining and Masson's trichrome staining showed that the hearts of MRL / lpr mice showed significant fibrosis and disordered cardiomyocyte arrangement phenotypes, which are very similar to the cardiac manifestations of hypertrophic heart disease in the clinic ( Figure 2 D and Figure 2G). Many previous studies have reported that the disintegration and destruction of cardiac muscle segments are often associated with heart diseases such as HCM and DCM. Therefore, we used cTnT immunofluorescence staining to mark cardiomyocytes and analyze the morphological changes of cardiac muscle segments in apoptosis-deficient mice. The cTnT staining images showed that 7-month-old Bim + / - and Bim - / - Myocardial sarcomere disintegration in mice Figure 1 J), and 8-month-old MRL / lpr mice also showed abnormal myocardial sarcomeres compared with WT mice ( Figure 2 H); In addition, we performed TOMM20 immunofluorescence staining on mitochondria marked by cardiomyocytes and found that apoptosis-deficient mice all had mitochondrial structural abnormalities ( Figure 1 K, Figure 2 I), indicating that apoptosis-deficient mice have myocardial damage and heart failure phenotypes. These data confirm the relationship between cardiac homeostasis and systemic apoptosis. Next, we wanted to know whether the amount of apoptotic metabolite apoVs was reduced in cardiac tissue, so we used Nanoflow and Western blotting to measure the number of apoptotic vesicles in cardiac tissue vesicles. Nanoflow data showed that the number of apoptotic vesicles in cardiac tissue of apoptosis-deficient mice was significantly decreased ( Figure 3 AB). In addition, we observed some free erythrocytes in the myocardial fibers of heart sections, and the number of erythrocytes infiltrating between myocardial fibers was significantly increased in apoptosis-deficient mice ( Figure 1 HI, Figure 2 JK). These data suggest that mice deficient in apoptosis display myocardial damage and heart failure. - / - ) mice always showed severe cardiac phenotypes, so in subsequent experiments, we selected heterozygous (Bim + / - ) for further research.

[0105] 2. Apoptotic vesicle infusion can rescue myocardial damage and heart failure in apoptosis-deficient mice

[0106] After finding that apoptosis-deficient mice showed cardiac phenotypes such as myocardial injury, heart failure, and decreased number of apoptotic vesicles in cardiac tissue, we next investigated whether exogenous infusion of apoVs could rescue the cardiac phenotypes of apoptosis-deficient mice. Staurosporine (STS) was used to induce apoptosis in healthy allogeneic mouse-derived mesenchymal stem cells (MSCs), and apoptotic vesicles were collected and supplemented into the Bim via tail vein injection. + / - Echocardiographic data showed that systemic infusion of apoptotic vesicles significantly improved Bim + / -The cardiac function of mice was manifested by the increase of cardiac function indexes EF% and FS% and the decrease of LVDs and LVDd ( Figure 4 AB). In addition, 4 months after apoVs infusion, the HCM phenotype of MRL / lpr mice was significantly alleviated, as reflected in the decrease of LVPW:s and LVPW:d ratios, the abnormal increase of EF% and FS% ratios, and the abnormal decrease of LVDs and LVDd ratios ( Figure 5 AB). Subsequently, we analyzed the histological changes of the heart by stereomicroscopy and HE staining and found that supplementation of exogenous apoptotic vesicles to apoptosis-deficient mice could rescue the Bim + / - Signs of cardiac hypertrophy ( Figure 4 CE). We further used HE staining and Masson trichrome staining to analyze the therapeutic effect of apoptotic vesicles on MRL / lpr mice and found that apoptotic vesicle treatment can significantly improve the disordered arrangement of cardiomyocytes in the heart tissue of MRL / lpr mice ( Figure 5 C) and myocardial fibrosis ( Figure 5 D) WGA staining data showed that systemic infusion of apoVs alleviated the pathogenesis of MRL / lpr mice and Bim + / - Mouse cardiomyocyte hypertrophy phenotype ( Figure 4 FG, Figure 5 EF). Then, we used cardiac troponin immunofluorescence staining to mark cardiac sarcomeres and TOMM20 immunofluorescence staining to mark cardiac mitochondria for cell histological analysis. Immunofluorescence data showed that apoptotic vesicles could significantly improve the destruction of cardiac sarcomeres and abnormal mitochondrial structure in apoptosis-deficient mice ( Figure 4 JK, Figure 5 IJ). In addition, we found that supplementation with apoVs slightly reduced the number of erythrocytes accumulated in cardiac tissue of apoptosis-deficient mice ( Figure 4 HI, Figure 5 GH). These data indicate that systemic infusion of apoVs can significantly rescue myocardial injury and manifestations of heart failure in apoptosis-deficient mice.

[0107] 3. Apoptotic vesicles can transfer the nuclear material they carry into the nucleus of cardiomyocytes

[0108] To further explore the relationship between apoptotic vesicles and cardiomyocytes, we intravenously injected DIR-labeled apoptotic vesicles into C57 / BL6 mice to track their distribution in tissues and organs in the mouse body. In vivo imaging data showed that a small amount of apoptotic vesicles were enriched in cardiac tissues ( Figure 6A). As factors such as fast blood flow and dense myocardium in cardiac tissue may hinder the enrichment of exogenous apoVs, we next verified whether cardiomyocytes can take up apoVs. Therefore, we isolated neonatal cardiomyocytes and co-cultured them with PKH26-labeled apoptotic vesicles. We found that cardiomyocytes can significantly take up apoptotic vesicles derived from allogeneic mesenchymal stem cells ( Figure 6 B); In addition, PKH26-labeled apoptotic vesicles were infused into mice via the tail vein for 12 hours, 24 hours, and 48 hours. We found that apoptotic vesicles could be taken up by cardiomyocytes, and over time, these apoptotic vesicles gradually approached the periphery of cardiomyocyte nuclei ( Figure 6 C). Our previous studies have shown that apoptotic vesicles contain more nuclear components, such as DNA fragments, histones, and nuclear structural proteins of organelles, compared with exosomes, so we hypothesized that apoptotic vesicles can transfer fresh and healthy nuclear materials to the nucleus of cardiomyocytes for utilization. To test this hypothesis, we co-cultured cardiomyocytes with apoptotic vesicles labeled with 5-ethyl-2-deoxyuridine (EdU), a DNA synthesis raw material mimic, for 24 hours. Fluorescence data showed that the DNA components carried by apoptotic vesicles can be embedded in the nucleus of cardiomyocytes ( Figure 6 D). In addition, after co-culture of apoptotic vesicles with cardiomyocytes for 24 hours, we found that apoptotic vesicles could upregulate the expression of nuclear structural proteins including histones H2A, H2B, H3 and H4 ( Figure 6 E). SERCA2a (sarcoplasmic / endoplasmic reticulum Ca2+-ATPase 2A) is an anti-hypertrophic protein of the heart, which is closely related to cardiac function and is often downregulated in heart failure. Therefore, we chose this indicator to evaluate the effect of apoptotic vesicles on cardiomyocytes; Western blotting data showed that apoptotic vesicles can significantly upregulate the expression of SERCA2a, indicating that apoptotic vesicles can maintain cardiomyocyte function ( Figure 6 F).

[0109] 4. Cardiomyocyte-derived extracellular vesicles contain a large amount of nuclear material and cause cardiomyocyte dysfunction

[0110] Our data showed that apoptotic vesicles can transfer the nuclear material they carry to the nucleus of cardiomyocytes. We then hypothesized that cardiomyocytes may expel unnecessary nuclear components in the form of extracellular vesicles and take in new nuclear components to maintain their own homeostasis and function. For the first time, we proposed a new cell renewal and replacement mechanism - a subcellular structure replacement method represented by "nuclear material replacement" to maintain cardiac homeostasis. To verify our hypothesis, we isolated newborn cardiomyocytes from 2-day-old SD rats to establish an in vitro model and found that compared with cardiac fibroblasts (FB), cardiomyocytes secreted a large number of extracellular vesicles during culture; the diameter of these cardiomyocyte-derived extracellular vesicles was mostly distributed between 100nm and 1000nm, and the potential was 18.95±0.51mV ( Figure 7 A). Previous studies have reported that there is rapid histone turnover in a small number of adult cardiomyocytes during the cycle. Therefore, we first analyzed the nuclear components of cardiomyocyte-derived extracellular vesicles, such as DNA and nuclear structural proteins such as histones. We used Hoechst dye to label the DNA in cardiomyocyte-derived extracellular vesicles, and immunofluorescence data showed that cardiomyocyte-derived extracellular vesicles contained many DNA components ( Figure 7 B). Next, we used SYTO-16 probe to DNA-label stem cell-derived apoptotic vesicles, cardiomyocyte-derived extracellular vesicles, and cardiac fibroblast-derived extracellular vesicles. The SYTO-16 probe can label DNA encapsulated within the membrane of the vesicles without any membrane permeabilization treatment. Nanoflow data showed that cardiomyocyte-derived extracellular vesicles and apoptotic vesicles contained more DNA nuclear material compared to cardiac fibroblast-derived vesicles ( Figure 7 CD). In addition, we isolated newborn mouse cardiomyocytes and adult mouse cardiomyocytes and found that there were many micronuclei in the cardiomyocyte cytoplasm ( Figure 7 E), which is characterized by being round or oval, separated from the main nucleus, and less than one-third of the main nucleus. In order to verify the differences in nuclear components between cardiomyocytes and other cell types, we further labeled the nuclear structural protein of histone H4. Immunofluorescence data showed that a large amount of nuclear structural protein of histone H4 was free in the cytoplasm of cardiomyocytes, which was different from other cells such as cardiac fibroblasts ( Figure 7 F). Next, we speculated that nuclear structural proteins were encapsulated by vesicles and excreted from cardiomyocytes. Therefore, we labeled the extracellular vesicle marker CD63 and the nuclear structural protein histone H4 in cardiomyocytes and found that CD63 and histone H4 co-localized both inside and outside cardiomyocytes ( Figure 7 G); by collecting cardiomyocyte-derived extracellular vesicles for further Western blotting analysis, it was found that cardiomyocyte-derived extracellular vesicles contained nuclear structural proteins of histones H2A, H2B, H3 and H4 ( Figure 8A). In addition, we found that cardiomyocyte-derived extracellular vesicles contained many organelles, such as mitochondria, lysosomes, and endoplasmic reticulum, which was confirmed in the Nanoflow data ( Figure 8 E), which indicates that cardiomyocytes release many intracellular components encapsulated by vesicles. After discovering this, we wanted to know the role of these cardiomyocyte-derived extracellular vesicles in cardiac homeostasis, so we co-cultured cardiomyocyte-derived extracellular vesicles with cardiomyocytes for 48 hours. Immunofluorescence data showed that cardiomyocytes can take up a large amount of cardiomyocyte-derived extracellular vesicles ( Figure 8 B), these excreted cardiomyocyte-derived extracellular vesicles further induce cardiomyocyte dysfunction, including oxidative DNA damage ( Figure 8 CD), these data suggest that myocardial cells excrete unnecessary nuclear substances through extracellular vesicles. If these excreted extracellular vesicles are not cleared in time, they will be taken up by myocardial cells again and cause myocardial damage.

[0111] 5. Red blood cells internalize and remove damaged nuclear components expelled by myocardial cells

[0112] Our results indicate that cardiomyocytes excrete unnecessary nuclear components and other substances through extracellular vesicles. The mechanism by which cardiomyocytes clear these dysfunctional cardiomyocyte nuclear materials to maintain cardiac homeostasis has been unclear. In this study, we found that erythrocytes exist freely between myocardial fibers at a constant numerical range, and when the myocardium is damaged, the number of erythrocytes between myocardial fibers increases significantly. Mature erythrocytes in mammals are the most numerous cells in the body and lack nuclei and organelles. The current field believes that their function in the body is to transport oxygen. Therefore, we would like to know the interaction between erythrocytes and cardiomyocytes. To verify the hypothesis, we first isolated circulating mature erythrocytes from adult mice, and then labeled cardiomyocytes and erythrocytes for co-culture analysis. High-content imaging videos show that cardiomyocytes continuously excrete large amounts of nuclear material into the extracellular space ( Fig. 9 A); Red blood cells residing around myocardial cells rapidly process and internalize the nuclear material expelled by these myocardial cells ( Fig. 9 A). In addition, we used a high-content imaging system to capture the interaction between erythrocytes and cardiomyocyte-derived extracellular vesicles. Fluorescence videos and images at different time points showed that cardiomyocyte-derived extracellular vesicles without erythrocytes gradually ruptured, resulting in significant leakage of nuclear fragments over time, forming a large number of irregular nuclear fragments free in the culture environment ( Fig.10 A); When myocardial cell-derived extracellular vesicles are co-cultured with erythrocytes, the nuclear components in the vesicles gradually aggregate into regular spheres and are then endocytosed by erythrocytes ( Fig.10C). Therefore, we stained the heart tissue of adult mice and labeled the red blood cells residing in the myocardial fibers. We found that there were red blood cells with nuclear components in the heart tissue, which was consistent with our findings in vitro ( Fig. 9 C). To confirm the hypothesis, we collected red blood cells from the cardiac cavity and circulating blood, and labeled the cells with Ter119 red blood cell marker and SYTO-16 DNA probe. Flow cytometry results showed that the proportion of red blood cells containing DNA components in the cardiac cavity blood was significantly higher than that in the circulating blood ( Fig. 9 D). In addition, we further used acetylphenylhydrazine (APH) to induce aplastic anemia model, in which mice have red blood cell dysfunction. Immunofluorescence data showed that in healthy mice, there were about 0.3 to 0.5 red blood cells around each cardiomyocyte, while in anemic mice, the number of red blood cells between myocardial fibers increased significantly ( Fig. 9 EF), severe myocardial damage ( Fig. 9 G). These data demonstrate that erythrocytes are closely associated with cardiomyocytes and maintain cardiac homeostasis by endocytosis and clearance of nuclear material that is not required by cardiomyocytes.

[0113] 6. Apoptotic vesicles rescue Dox-induced heart failure

[0114] Since systemic infusion of apoptotic vesicles can significantly rescue heart failure and myocardial damage in apoptosis-deficient mice, we next explored whether exogenous infusion of apoptotic vesicles can alleviate the heart failure phenotype induced by doxorubicin (Dox). Survival curve data showed that infusion of apoptotic vesicles can prevent Dox-induced heart failure mice from dying ( Fig.11 B). After 4 weeks of apoptotic vesicle treatment, echocardiographic analysis showed that apoptotic vesicle treatment could significantly maintain the cardiac function of mice with heart failure, as shown by increased EF% and FS% values ​​and decreased LVDs and LVDd values ​​( Fig.11 CD). We then collected heart samples for further histopathological analysis, and in vivo imaging data showed that the heart size of Dox-induced heart failure mice was smaller than that of sham-operated mice, and apoptotic vesicle treatment could alleviate this abnormal cardiac phenotype ( Fig.11 EF), which was also confirmed by H&E staining data ( Fig.11 G). In addition, WGA staining data confirmed that infusion of apoptotic vesicles could rescue the abnormally small cardiomyocytes in Dox-induced heart failure mice ( Fig.11Next, we analyzed the structural changes of myocardial fibers by cTnT immunofluorescence staining. The data showed that compared with the sham-operated mice, myocardial sarcomeres were destroyed in myocardial fibers of Dox-induced heart failure mice. Systemic infusion of apoptotic vesicles significantly improved the abnormalities of myocardial sarcomeres in Dox-induced heart failure mice ( Fig.11 J). To confirm the therapeutic effect of apoptotic vesicles, we further analyzed the changes in myocardial mitochondria by TOMM20 immunofluorescence staining, which is considered to be one of the most important structural changes in heart failure. The data showed that compared with the sham-operated mice, the myocardial mitochondria of Dox-induced heart failure mice showed abnormal swelling, and apoptotic vesicle infusion could also significantly alleviate this pathological manifestation of Dox-induced heart failure mice ( Fig.11 K). These data confirm that exogenous infusion of apoptotic vesicles has a promising therapeutic effect, which means that the use of apoptotic vesicles to treat heart failure is a promising therapeutic strategy.

[0115] 7. There is a renewal mechanism in the body for myocardial cells through subcellular structure replacement

[0116] By constructing a non-fluorescent C57BL / 6 mouse bone marrow transplant chimeric model, the regenerative capacity of the C57BL / 6 mouse bone marrow was destroyed by X-ray irradiation, and the green fluorescent whole bone marrow cells in the GFP fluorescent mouse were immediately transplanted into the irradiated C57BL / 6 mouse ( Fig.12 A); 4 months after surgery, the whole bone marrow cells of the chimeric model mice were extracted for cell flow cytometry. The results showed that most of the cells in the bone marrow of the chimeric mice were replaced with cells with GFP green fluorescence ( Fig.12 B); The heart tissues of chimeric mice were collected and analyzed by immunofluorescence staining; the results showed that the cardiomyocytes of chimeric mice carried a large amount of GFP green fluorescent protein ( Fig.12 D), by transplanting the C57BL / 6 mouse heart as a donor into the neck of a GFP fluorescent mouse, it was confirmed after surgery that the ectopic heart in the neck restored cardiac beating function; the mice were raised for 2 weeks, and the donor heart and the original heart of the recipient mouse were collected ( Fig.12 C), immunofluorescence staining results showed that in the transplanted C57BL / 6 mouse heart, the cardiomyocytes carried a large amount of GFP fluorescent protein that was not originally present, indicating that the subcellular structure of the cardiomyocytes in the donor heart had been replaced with the components in the GFP mouse body ( Fig.12 E); The above experimental results indicate that there is a mechanism for the renewal and replacement of the subcellular structure of myocardial cells in the body.

[0117] In this study, we first discovered the relationship between cardiac homeostasis and apoptosis, and demonstrated this through myocardial injury and heart failure phenotypes in apoptosis-deficient mice. In addition, exogenous infusion of apoptotic vesicles can significantly improve cardiac function in apoptosis-deficient mice and Dox-induced mice, which means that the use of apoptotic vesicles to treat heart failure is a promising therapeutic strategy. Mechanistically, we found that apoptotic vesicles can transfer nuclear materials into the nucleus of cardiomyocytes and maintain their function, and cardiomyocytes expel many unnecessary nuclear materials from cells through extracellular vesicles; therefore, we creatively proposed a new concept named "nuclear component renewal mechanism" to describe the process of exocytosis and endocytosis of nuclear materials in cardiomyocytes through extracellular vesicle media. Interestingly, we also found for the first time that erythrocytes residing in myocardial fibers have important functions in the processing, endocytosis and removal of unnecessary nuclear materials by cardiomyocytes, which reveals a completely new and important function of erythrocytes.

[0118] In our body, almost every tissue undergoes routine cell renewal through programmed cell death as part of normal healthy life. Apoptosis is one of the most important programmed cell death pathways, which is involved in tissue morphogenesis during development and maintains the homeostasis of tissues after birth by removing unnecessary cells; 50-70 billion cells in our body undergo apoptosis every day. During apoptosis, a large number of apoptotic metabolites are released, called apoptotic vesicles (apoVs). In recent years, the role and physiological significance of apoVs have gradually been emphasized. Compared with exosomes, it contains more nuclear components, including nucleic acids, nuclear proteins and organelles; they are essential elements for maintaining the homeostasis of mesenchymal stem cells, maintaining the immune microenvironment, nourishing the skin and storing the homeostasis of the liver. In addition, the medicinal value of apoptotic vesicles has also been gradually discovered, showing good application prospects in the treatment of multiple myeloma, systemic lupus erythematosus, hemophilia, hemostasis, sepsis, osteoporosis, diabetes, chronic inflammation and other treatment fields. Since cardiomyocyte apoptosis always occurs in myocardial infarction and cardiotoxicity, this may lead to the neglect of the importance of normal systemic apoptosis in maintaining cardiac homeostasis. In our study, we found the necessity of systemic apoptosis and its metabolite apoVs for maintaining cardiac homeostasis. In addition, we developed an effective method to treat heart failure using apoptotic vesicles, which indicates a very promising strategy for the treatment of heart failure. In the adult mammalian heart, cardiomyocytes are a long-lived, low-proliferation, specialized, and structurally unique cell type. They are constantly subjected to strong mechanical stress, DNA oxidative damage, and high metabolic demands of heart beating. However, unlike other cell types that are mainly renewed by apoptosis and then maintain tissue homeostasis through conventional stem cell replacement and cell proliferation, cardiomyocytes are believed to lack stem cell replacement mechanisms, and their apoptosis often leads to serious heart diseases. The contradiction between cell properties and their functional properties attracted our attention, which led us to think about whether there is a special replacement mechanism in the body to renew this unique cell type to maintain tissue homeostasis. A study has discovered for the first time a unique mechanism by which cardiomyocytes maintain cardiac homeostasis by eliminating dysfunctional mitochondria through the mitophagy pathway, extruding cellular material through the outer layer, which is then taken up and processed by macrophages residing between cardiomyocyte fibers. Our findings have several potential implications. First, we found that apoptotic vesicles transfer nuclear components to cardiomyocytes, including nucleic acids and upregulated expression of histone nuclear proteins; second, we found that cardiomyocytes extrude many unwanted nuclear materials out of the cell through extracellular vesicles, and these unwanted nuclear materials can cause cardiomyocyte damage; third, we proposed a new cell replacement theory that mainly applies to the renewal and replacement mechanism of cardiomyocytes.The renewal mechanism of these subcellular structures is similar to the principle of "Ship of Theseus" in philosophy, describing a ship named "Theseus" that can sail on the sea for hundreds of years, thanks to the constant removal of damaged planks and replacement of new ones to maintain the function of the ship. Here, we found that cardiomyocytes excrete unnecessary nuclear materials, and apoptotic vesicles transfer renewed nuclear components to cardiomyocytes, forming a cycle, similar to the "yin and yang balance" theory, emphasizing the importance of integrity, vitality and balance. Therefore, we named this process the "nuclear component renewal mechanism" of cardiomyocytes. Our study confirmed the important role of apoptotic metabolites apoptotic vesicles in maintaining cardiomyocyte homeostasis, as well as the nuclear renewal mechanism of cardiomyocytes to maintain cardiac function. Red blood cells are the most numerous cells in the body, have the function of transporting oxygen, and participate in immune regulation processes. In mammals, mature red blood cells do not have nuclei and organelles. We found that red blood cells reside in myocardial fibers, and the ratio of red blood cells to cardiomyocytes is constant, and this value always increases when the myocardium is damaged. This also reminds us of the relationship between anemia and heart failure, as well as heart disease caused by long-term storage and transfusion in clinical practice. In our study, we found that enucleated erythrocytes have the ability to process, endocytose, and remove unwanted nuclear components from cardiomyocytes to maintain cardiac homeostasis. Therefore, this finding confirms a role and a completely new function of erythrocytes in maintaining cardiac homeostasis. Our study identified a previously unknown mechanism of nuclear component replacement to maintain cardiomyocyte self-renewal and cardiac function. In addition, we revealed that apoptotic vesicles provide nuclear material to cardiomyocytes, suggesting that the use of apoptotic vesicles is a promising therapeutic strategy for the treatment of heart failure.

[0119] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. Application of apoptotic vesicles in the preparation of drugs for preventing or treating heart failure.

2. Application of apoptotic vesicles in the preparation of drugs for preventing or treating myocardial damage.

3. Application of apoptotic vesicles in the preparation of drugs for improving cardiomyocyte function.

4. Application of apoptotic vesicles in the preparation of drugs for improving cardiac function.

5. Application of apoptotic vesicles in the preparation of drugs for preventing or treating heart diseases.

6. The use according to claim 1, characterized in that: The heart failure is heart failure caused by abnormal myocardial cell metabolism.

7. The use according to claim 1, characterized in that: The heart failure is apoptosis defect-induced heart failure.

8. The use according to claim 1, characterized in that: The heart failure is heart failure caused by DOX.

9. The use according to any one of claims 1 to 5, characterized in that: The apoptotic vesicles are apoptotic vesicles derived from mesenchymal stem cells.

Citation Information

Cited By

  • Erythrocyte vesicles coated with epo and methods of making and using the same

    CN122998409A